Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 24Breast Neoplasms 13Triple Negative Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 3Thymoma 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Nasopharyngeal Carcinoma 2Locally Advanced Pancreatic Cancer 2Borderline Resectable Pancreatic Cancer 2Biliary Tract Neoplasms 2Advanced Pancreatic Cancer 2Advanced Gastric Cancer 2Uterine Cervical Neoplasms 1Thromboembolism 1Thoracic Neoplasms 1Stage IV Gastric Cancer With Metastasis 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Lung 1Small Cell Lung Carcinoma 1Resectable Biliary Tract Cancer 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Muscle-Invasive Bladder Carcinoma 1Melanoma 1Lung Diseases 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Locally Advanced Cervical Carcinoma 1

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × 130-nm albumin-bound paclitaxel × Clear all
NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡